Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Inclusion criteria: Medical diagnosis of persistent asthma for at least 12 months whose: * airway inflammation likely to be eosinophilic, * asthma partially controlled or uncontrolled on ICS plus LABA therapy. * On a stable dose of either Fluticasone/Salmeterol, Budesonide/Formoterol, Mometasone/Formoterol combination therapy for at least 1 month prior to screening. * Signed an Informed Consent Form and Health Insurance Portability and Accountability Act (HIPAA) Authorization Form. Exclusion criteria: * Less than 18 years or greater than 65 years of age. * Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further evaluation. * Chronic obstructive pulmonary disease and/or other lung diseases impairing Pulmonary Function Tests. * Beta-adrenergic receptor blockers required for any reason. * Current smoker or cessation of smoking within the 6 months prior to screening. * Previous smoking with a smoking history \>10 cigarette pack/years. * Participation in another study within 6 months prior to screening if the study medication was an antibody or within 30 days prior to screening for all other study medications. * Known or suspected non-compliance, alcohol or drug abuse. * Inability to follow the procedures of the study (e.g, due to language problems, psychological disorders). * Concomitant severe diseases or diseases for which the use of ICS or LABA were contraindicated. * Known allergy to doxycycline or related compounds. * Pregnancy …